|
|
 |
|
Viewing report
|
|
|
|
The Pharmaceutical Market: Peru
Espicom Business Intelligence Ltd, Oct 2011, Pages: 130
THE PHARMACEUTICAL MARKET: PERU - REVIEW
Peru is often overlooked when discussing the rapid-growth economies of South America. While it has neither the size nor the wealth of Brazil or Argentina, the country has a population that exceeds 30 million in 2011, and has recorded strong economic growth in recent years. According to the Economist Intelligence Unit (EIU), GDP growth is expected to increase by 6.5% in real terms in 2011. GDP per capita wealth has risen, especially around Lima, leading to a sizeable urban population that demands improved healthcare and has the ability to pay for it. This economic environment is expected to encourage drug consumption. In legal terms, Peru is continuing to implement its National Strategic Plan to combat counterfeiting and piracy.
The Peruvian pharmaceutical market is the second smallest in the region. The market is expected to increase by a moderate CAGR in dollar terms between 2011 and 2016. Pharmaceutical expenditure per capita is the lowest in the region. This means that there are growth opportunities, as the economy is expected to perform well in the forecast period. The market increased five times between 1995 and 2010. In January 2011, the Israeli Teva Pharmaceutical Industries announced that it was acquiring Infarmasa from The Rohatyn Group (TRG) and Altra Investments. Teva commented that the combination of Medco, which is Teva's existing operation in Peru, and Infarmasa would create one of the top two pharmaceutical companies in the country.
Major Peruvian pharmaceutical wholesalers include Química Suiza, Albis and Drokasa. Química Suiza imports, produces, markets and distributes pharmaceuticals, personal care products and equipment for the industrial sector. The company has offices in Arequipa, Chiclayo, Cusco, Huancayo, Iquitos, Lima, Piura and Trujillo. Química Suiza also has a regional presence with subsidiaries in Bolivia, Colombia, Ecuador and Venezuela. The company has six divisions. In February 2011, Química Suiza acquired the pharmacy chain Boticas BTL for an undisclosed transaction value. With this acquisition, Química Suiza will control about 300 pharmacies in Peru; the company already owns Boticas Mifarma in the retail pharmacy sector.
ENHANCED STRATEGIC INTELLIGENCE
These highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting the pharmaceutical market in context. The reports provide:
- Five-year projections for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators.
- Specialised intelligence on OTCs, generics, biologics and biosimilars.
- Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the series.
- A separate statistical health file, comprising health expenditure, health infrastructure, health services and health personnel.
- The reports are updated quarterly, providing you with the latest information for a full year. In addition, the service will keep you up to date with market and industry news on a regular basis.
HEALTHCARE STATISTICS
A comprehensive tabula review, comprising demographics, epidemiology, health expenditure, hospital and primary care infrastructure & services and healthcare personnel, is additionally included.
Customers who bought this item also bought
The Pharmaceutical Market: Serbia
The Pharmaceutical Market: Philippines
The Pharmaceutical Market: Brazil
The Pharmaceutical Market: Hungary
The Pharmaceutical Market: Estonia
The Pharmaceutical Market: Pakistan
The Pharmaceutical Market: Argentina
The Pharmaceutical Market: Sweden
Pricing and Reimbursement in the US - Non-LIS Beneficiaries Not Covered by Medicare Coverage Gap to Gain from Reduction in Out-of-Pocket Expenditure for Generic Drugs
The Outlook for Pharmaceuticals in the Middle East and North Africa
|
|
|
|
